Quality Level
assay
≥98% (HPLC)
form
solid
solubility
DMSO: ≥28 mg/mL
originator
Johnson & Johnson
storage temp.
2-8°C
SMILES string
O=C(Nc1ccccc1)N2CCN(CC2)c3nc(ns3)-c4ccccc4
InChI
1S/C19H19N5OS/c25-18(20-16-9-5-2-6-10-16)23-11-13-24(14-12-23)19-21-17(22-26-19)15-7-3-1-4-8-15/h1-10H,11-14H2,(H,20,25)
InChI key
BHBOSTKQCZEAJM-UHFFFAOYSA-N
Biochem/physiol Actions
JNJ-1661010 is a potent and selective fatty acid amide hydrolase (FAAH) inhibitor with >100-fold preferentially selective for FAAH-1 over FAAH-2. FAAH in an integral membrane enzyme within the amidase-signature family. It catalyzes the hydrolysis of several endogenous biologically active lipids and involves in a variety of physiological and pathological processes, including synaptic regulation, regulation of sleep and feeding, locomotor activity, pain and inflammation.
JNJ-1661010 is a potent and selective fatty acid amide hydrolase (FAAH) inhibitor.
Features and Benefits
This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Torsten Lowin et al.
Arthritis research & therapy, 17, 321-321 (2015-11-17)
The endocannabinoid system modulates function of immune cells and mesenchymal cells such as fibroblasts, which contribute to cartilage destruction in rheumatoid arthritis (RA). The aim of the study was to determine the influence of N-acylethanolamines anandamide (AEA), palmitoylethanolamine (PEA) and
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| J3205-5MG | 04061832947983 |